A vaccine targeting the immune system has shown promise in intercepting cancer in patients with Lynch syndrome. Research has also explored the potential of immune-targeting vaccines in other high-risk and premalignant settings, including pancreatic cancer. The development of cancer vaccines, including one for Lynch syndrome, is an area of ongoing research, with some studies investigating specific approaches such as targeting enzymes or using mRNA technology.